On Monday, Viracta Therapeutics Inc (NASDAQ: VIRX) opened higher 4.44% from the last session, before settling in for the closing price of $0.23. Price fluctuations for VIRX have ranged from $0.20 to $1.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 134.94% over the last five years. Company’s average yearly earnings per share was noted 32.07% at the time writing. With a float of $27.71 million, this company’s outstanding shares have now reached $39.09 million.
The firm has a total of 40 workers. Let’s measure their productivity. In terms of profitability, gross margin is 38.08%, operating margin of -6707.32%, and the pretax margin is -6143.09%.
Viracta Therapeutics Inc (VIRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Viracta Therapeutics Inc is 29.69%, while institutional ownership is 21.82%. The most recent insider transaction that took place on Feb 27 ’24, was worth 2,493. In this transaction CFO and COO of this company sold 3,405 shares at a rate of $0.73, taking the stock ownership to the 102,306 shares. Before that another transaction happened on Nov 30 ’23, when Company’s President and CEO bought 52,094 for $0.49, making the entire transaction worth $25,734. This insider now owns 52,094 shares in total.
Viracta Therapeutics Inc (VIRX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.33 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.3) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.07% per share during the next fiscal year.
Viracta Therapeutics Inc (NASDAQ: VIRX) Trading Performance Indicators
Check out the current performance indicators for Viracta Therapeutics Inc (VIRX). In the past quarter, the stock posted a quick ratio of 1.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Viracta Therapeutics Inc (VIRX)
Analysing the last 5-days average volume posted by the [Viracta Therapeutics Inc, VIRX], we can find that recorded value of 0.24 million was lower than the volume posted last year of 0.27 million. As of the previous 9 days, the stock’s Stochastic %D was 48.60%. Additionally, its Average True Range was 0.02.
During the past 100 days, Viracta Therapeutics Inc’s (VIRX) raw stochastic average was set at 6.15%, which indicates a significant decrease from 72.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.26% in the past 14 days, which was lower than the 94.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2529, while its 200-day Moving Average is $0.5969. Now, the first resistance to watch is $0.2524. This is followed by the second major resistance level at $0.2647. The third major resistance level sits at $0.2802. If the price goes on to break the first support level at $0.2246, it is likely to go to the next support level at $0.2091. Now, if the price goes above the second support level, the third support stands at $0.1968.
Viracta Therapeutics Inc (NASDAQ: VIRX) Key Stats
There are currently 39,272K shares outstanding in the company with a market cap of 9.46 million. Presently, the company’s annual sales total 0 K according to its annual income of -51,060 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,830 K.
